Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial.

TPS1139 Background: Cisplatin has shown activity in BRCA associated breast cancer patients but generally the use of cisplatin in breast cancer has been hampered by high toxicity and low response rates of approximately 10% (Baselga et al. JCO, 2013; 31:2586-2592.). We address both issues in an ongoing phase 1 study with a third generation liposomal cisplatin which is activated by secretory phospholipase A2 (sPLA2) present on the tumor cells, and in parallel by selecting patients with a companion diagnostic for an optimal cisplatin sensitivity microRNA profile and expression of sPLA2. Methods: A validated response prediction method is used in the cisplatin sensitivity prediction. The method uses cell line drug sensitivity data and cell line microarray data and clinical tumor big data analysis (Wang et al. J Natl Cancer Inst; 2013;105:1284–1291.). When the profile was probed on a published cohort of BC there were patients in all breast cancer subgroups that were predicted high likely sensitive. From the lite...